Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    Lazuvapagon

    go.drugbank.com/drugs/DB19046
    Investigational

    Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects).

    Synonyms: (4s)-n-((2s)-1-hydroxypropan-2-yl)-methyl-1-(2-methyl-4-(3-methyl-1h-pyrazol-1-yl)benzoyl)-2,3,4,5-tetrahydro-1h-1-benzazepine-4-carboxamide, 1h-1-benzazepine-4-carboxamide, 2,3,4,5-tetrahydro-n-((1s)-2-hydroxy-1-methylethyl)-4-methyl-1-(2-methyl-4-(3-methyl-1h-pyrazol-1-yl)benzoyl)-, (4s)-
  2. Drug

    Rimexolone

    go.drugbank.com/drugs/DB00896
    ApprovedWithdrawn

    It is used to treat inflammation in the eye. It is marketed as Vexol.

  3. Drug

    Bifonazole

    go.drugbank.com/drugs/DB04794
    Approved

    Bifonazole is an azole antifungal drug.

  4. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.

  5. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

    Synonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
  6. Drug

    Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16923
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  7. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB22669
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB22671
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB31654
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen